Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.

Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, Finkelstein D, Hasan T.

Cancer Res. 2010 Nov 15;70(22):9319-28. doi: 10.1158/0008-5472.CAN-10-1783. Epub 2010 Nov 9.

2.

Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.

del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, Pogue B, Hasan T.

J Natl Cancer Inst. 2005 Oct 19;97(20):1516-24.

PMID:
16234565
3.

Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model.

Celli JP, Rizvi I, Evans CL, Abu-Yousif AO, Hasan T.

J Biomed Opt. 2010 Sep-Oct;15(5):051603. doi: 10.1117/1.3483903.

4.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

5.

Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells.

Erices R, Bravo ML, Gonzalez P, Oliva B, Racordon D, Garrido M, Ibañez C, Kato S, Brañes J, Pizarro J, Barriga MI, Barra A, Bravo E, Alonso C, Bustamente E, Cuello MA, Owen GI.

Reprod Sci. 2013 Dec;20(12):1433-46. doi: 10.1177/1933719113488441. Epub 2013 May 7.

6.

PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D ovarian cancer model.

Rizvi I, Anbil S, Alagic N, Celli J, Zheng LZ, Palanisami A, Glidden MD, Pogue BW, Hasan T.

Photochem Photobiol. 2013 Jul-Aug;89(4):942-52. doi: 10.1111/php.12065. Epub 2013 Apr 4. Erratum in: Photochem Photobiol. 2013 Jul-Aug;89(4):942. Celli, Jonathan P [corrected to Celli, Jonathan].

7.

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring.

Zhong W, Celli JP, Rizvi I, Mai Z, Spring BQ, Yun SH, Hasan T.

Br J Cancer. 2009 Dec 15;101(12):2015-22. doi: 10.1038/sj.bjc.6605436. Epub 2009 Nov 17.

9.

Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT.

Evans CL, Abu-Yousif AO, Park YJ, Klein OJ, Celli JP, Rizvi I, Zheng X, Hasan T.

PLoS One. 2011;6(8):e23434. doi: 10.1371/journal.pone.0023434. Epub 2011 Aug 18.

10.

Photodynamic therapy as an effective therapeutic approach in MAME models of inflammatory breast cancer.

Aggarwal N, Santiago AM, Kessel D, Sloane BF.

Breast Cancer Res Treat. 2015 Nov;154(2):251-62. doi: 10.1007/s10549-015-3618-6. Epub 2015 Oct 26.

11.

Calculation of singlet oxygen dose using explicit and implicit dose metrics during benzoporphyrin derivative monoacid ring A (BPD-MA)-PDT in vitro and correlation with MLL cell survival.

Weston MA, Patterson MS.

Photochem Photobiol. 2011 Sep-Oct;87(5):1129-37. doi: 10.1111/j.1751-1097.2011.00942.x. Epub 2011 Jul 7.

PMID:
21575000
12.

Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.

Weigel MT, Rath K, Alkatout I, Wenners AS, Schem C, Maass N, Jonat W, Mundhenke C.

Oncology. 2014;87(4):232-45. doi: 10.1159/000363656. Epub 2014 Aug 8.

PMID:
25116401
13.

Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas.

Cincotta L, Szeto D, Lampros E, Hasan T, Cincotta AH.

Photochem Photobiol. 1996 Feb;63(2):229-37.

PMID:
8657737
14.

Intracellular localization and concentration as well as photodynamic effects of benzoporphyrin derivative monoacid ring A in four types of rodent tumor cells.

Osaki T, Takagi S, Hoshino Y, Okumura M, Fujinaga T.

Cancer Lett. 2006 Nov 18;243(2):281-92. Epub 2006 Jan 18.

PMID:
16412570
15.

Impact of treatment response metrics on photodynamic therapy planning and outcomes in a three-dimensional model of ovarian cancer.

Anbil S, Rizvi I, Celli JP, Alagic N, Pogue BW, Hasan T.

J Biomed Opt. 2013 Sep;18(9):098004. doi: 10.1117/1.JBO.18.9.098004.

16.

Metformin and epithelial ovarian cancer therapeutics.

Patel S, Kumar L, Singh N.

Cell Oncol (Dordr). 2015 Oct;38(5):365-75. doi: 10.1007/s13402-015-0235-7. Epub 2015 Aug 13.

PMID:
26266765
17.

Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model.

Molpus KL, Kato D, Hamblin MR, Lilge L, Bamberg M, Hasan T.

Cancer Res. 1996 Mar 1;56(5):1075-82.

18.
19.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
20.

Supplemental Content

Support Center